ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Could FTC scrutiny of the Roche-Spark merger scuttle future pharma deals? Analysts are fretting
August 04, 2019When Roche delayed its planned $4.8 billion purchase of gene therapy developer Spark Therapeutics for the fifth time earlier this week, citing the Federal Trade Commission's (FTC's) review of the deal, one burning question emerged among pharma watchers: W
Pharma Sources Insight January 2025
